Clinical trials: Framingham Risk Score More Than 20 Percent
Diabetes, Chronic Kidney Disease
The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH
Cardiovascular disease (disease of the heart and blood vessels) is one of the leading causes of death in Canada. It also carries a financial burden on the Canadian economy with a yearly cost close to $21 billion divided between…
- Conditions
- Diabetes, Chronic Kidney Disease, Established Atherosclerotic Vascular Disease, Framingham Risk Score More Than 20 Percent
- Trial name
- RxEACH (NCT01979471)
- Testing
- Advanced Care
- Where
- Canada
- Volunteers
- 723 people
- Sponsor
- University of Alberta